FibroGen Inc (NASDAQ:FGEN) does about 935.96K shares in volume on a normal day but saw 1533354 shares change hands in the recent trading day. The company now has a market cap of 31.24M USD. Its current market price is $0.31, marking a decrease of -3.22% compared to the previous close of $0.32. The 52 week high reached by this stock is $1.53 whilst the lowest price level in 52 weeks is $0.18. The script in recent trading has seen the stock touch a high of $28 and a low of $28.
2 analysts observing the FibroGen Inc (FGEN) stock have set the 12-month price targets for the company’s shares at between $28 and $28. The consensus objective for the share price is $10.00, suggesting that the stock has a potential upside of 96.9% over the period. The median price target is 98.89% away from the current levels at $28.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 08, 2023 when BofA Securities downgraded the stock to “Underperform” and issued a price target of between $4 and $2.
The current price level is -1.02%, 1.17%, and -21.03% away from its SMA20, SMA50, and SMA200 respectively, with the FGEN price moving below the 50-day SMA on current market day. FibroGen Inc (FGEN) stock is up 2.62% over the week and 0.39% over the past month. Its price is -41.61% year-to-date and -74.02% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.09 and -0.49 for whole year. Expected sales for next quarter are $2.9M, which analysts say will come at $10M for the current fiscal year and next year at $9.6M. In addition, estimates put the company’s current quarterly revenue at an average of $2.88M.
Its 12-month price target is $28. To reach the target analysts have set, the stock logically needs to grow 96.9 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $28, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $28.
Outstanding shares total 101.04M with insiders holding 1.72% of the shares and institutional holders owning 33.02% of the company’s common stock. The beta has a value of 0.83. Price to sales ratio is 0.30.
